SCHEMBL4995086

SCHEMBL4995086

CCOC(=O)Cc1cc(O[C@@H]2CCN(Cc3ccccc3)C2)cc2ccoc12

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHEK2 O96017 1/20 0.41
OPRK1 P41145 1/20 0.41
ROCK1 Q13464 5/20 0.41
ROCK2 O75116 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.40
KCNH2 Q12809 2/20 0.40
ATM Q13315 1/20 0.40
MAOA P21397 2/20 0.40
MAOB P27338 2/20 0.40
CCR2 P41597 1/20 0.40
BCHE P06276 2/20 0.40
ACHE P22303 1/20 0.40
CCR8 P51685 1/20 0.40
DRD2 P14416 2/20 0.40
DRD4 P21917 2/20 0.40
MCHR1 Q99705 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4995093 1.00 CHEK2 (0.41) CHEK2OPRK1ROCK1ROCK2L3MBTL1
SCHEMBL27598151 0.89 CHEK2 (0.45) CHEK2OPRK1ROCK1ROCK2KCNH2
SCHEMBL27598152 0.89 CHEK2 (0.45) CHEK2OPRK1ROCK1ROCK2KCNH2
SCHEMBL4991838 0.88 OPRK1 (0.48) CHEK2OPRK1ROCK1ROCK2KCNH2
SCHEMBL4991844 0.88 OPRK1 (0.48) CHEK2OPRK1ROCK1ROCK2KCNH2
SCHEMBL5253318 0.82 OPRK1 (0.54) CHEK2OPRK1ROCK1ROCK2KCNH2
SCHEMBL6921844 0.79 L3MBTL1 (0.51) CHEK2OPRK1L3MBTL1ATMBCHE
SCHEMBL6921847 0.79 SIGMAR1 (0.50) L3MBTL1ATMBCHEMCHR1
SCHEMBL5252268 0.74 HRH3 (0.53) OPRK1ROCK1ROCK2KCNH2MAOA
SCHEMBL14592716 0.72 CHEK2 (0.54) CHEK2OPRK1L3MBTL1DRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7405305-B2 Pyrrole-2, 5dione derivatives and their used as GSK-3 inhibitors ELI LILLY AND COMPANY (US) 2008-07-29 US disclosed
EP-1487822-B1 PYRROLE-2,5-DIONE DERIVATIVES AND THEIR USE AS GSK-3 INHIBITORS LILLY CO ELI (US) 2007-08-01 EP disclosed
US-20050288321-A1 Kinase inhibitors ELI LILLY AND COMPANY 2005-12-29 US disclosed
EP-1487822-A2 PYRROLE-2,5-DIONE DERIVATIVES AND THEIR USE AS GSK-3 INHIBITORS ELI LILLY AND COMPANY (US) 2004-12-22 EP disclosed
WO-2003076398-A2 PYRROLE-2, 5-DIONE DERIVATIVES AND THEIR USE AS GSK-3 INHIBITORS ELI LILLY AND COMPANY (US) 2003-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288321-A1 Kinase inhibitors ABL1, MAP3K20, MAP3K19 CHEK2 51/4885OPRK1 1815/4885ROCK1 383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.